Related Experiment Video
Updated: Aug 12, 2026
07:12
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
[Prophylactic parathyroidectomy for familial parathyroid carcinoma]
O Gimm1, K Lorenz, P Nguyen Thanh
1Klinik für Allgemein-, Viszeral- und Gefässchirurgie, Martin-Luther-Universität Halle-Wittenberg. oliver.gimm@medizin.uni-halle.de
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|January 19, 2006
Summary
Parathyroid carcinoma is rare, but HRPT2 gene mutations are key in hyperparathyroidism jaw tumor (HPT-JT) syndrome. Genetic testing is crucial for patients with parathyroid carcinoma, as mutations are found in up to 20% of sporadic cases.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Context:
- Parathyroid carcinoma is a rare endocrine malignancy.
- Hyperparathyroidism jaw tumor (HPT-JT) syndrome is associated with germline HRPT2 mutations.
- Parathyroid carcinoma develops in 10-15% of HPT-JT syndrome patients.
Purpose:
- To review clinical and molecular genetic data of parathyroid carcinoma patients.
- To assess the role of HRPT2 mutations in sporadic and familial cases.
- To provide recommendations for screening and genetic testing.
Summary:
- This review analyzes data from approximately 100 patients with parathyroid carcinoma, including three new cases.
- Osteofibromas, indicative of HPT-JT syndrome, are present in only 30% of patients.
- Uniglandular disease is observed in about 80% of cases.
- Germline HRPT2 mutations are identified in up to 20% of patients with seemingly sporadic parathyroid carcinoma.
Impact:
- Highlights the importance of HRPT2 mutation analysis in all parathyroid carcinoma patients.
- Suggests thorough screening for at-risk individuals.
- Indicates that prophylactic parathyroidectomy cannot be generally recommended at this time.
